On 22 June, Gilead, the pharmaceutical company based in California that makes remdesivir, said it will begin testing an inhaled form of their experimental COVID-19 therapy. Currently, patients can only receive the drug by intravenous infusion provided under the supervision of medical experts. In a letter to the Web site, President and CEO David O’Day of Gilead published company said this week healthy volunteer screening starts in a phase 1 study of a version administered intranasally to remdesivir participate. Phase 1 studies are designed to evaluate the safety to determine an experimental treatment first practice to move its effectiveness. The shape remdesivir IV-administered is still being reviewed, along with other drugs, including the most seriously ill patients admitted to the hospital COVID-19. Preliminary data from these studies suggest that remdesivir can help patients recover faster than patients who did not receive the infusions. Since the drug is not yet approved; Patients can only receive or participate in a trial, or if seriously ill, the Food and Drug Administration (doctors can prescribe the drug if other therapies have worked) for an emergency permit are. The company also announced in its letter of 22 June to 19 COVID are patients with less severe symptoms, in the hope that with remdesivir investigate the drug can be before the disease some people the worst symptoms of respiratory distress and failure help ward. Picture copyright by Kenji Aoki for TIME
Gilead is testing an inhalable form of intravenous Remdesivir
